ỨNG DỤNG QUY TRÌNH TRUYỀN NHANH RITUXIMAB TẠI BỆNH VIỆN K

Abstract

Objective: To evaluate the safety, treatment efficacy and cost-effectiveness of applying the rapid rituximab infusion procedure. Subjects and methods: A cross-sectional descriptive prospective study was conducted on 278 patients with non-Hodgkin lymphoma treated with the rapid rituximab infusion procedure at the Hematologic Oncology Department, K Hospital from January 2025 to October 2025. Results: The average age is 57; The male/female ratio is ~1.41; 88.1% of patients were treated initially, the rate of stage 4 was 27%; stage 2 was 25%; stage 3 was 20%; stage 1 was 16%; the pathological anatomy of DLBCL was the majority 63.6%; the complete response rate was 76.6%; partial response was 16.2%; the disease remained unchanged 1.4%; the disease progressed 5.8%; The rate of patients suffered from infusion reactions with Rituximab was 3.6%, of which 2.2% of patients had reactions when receiving Rituximab for the first time according to the conventional procedure and 1.4% of patients had reactions when receiving Rituximab for the second and third times; the rapid rituximab infusion procedure shortened the time by 135 minutes compared to the conventional infusion procedure; Use of biosimilar formulations of rituximab results in comparable efficacy and cost savings. Conclusion: Applying the rapid rituximab infusion procedure ensures safety as well as treatment effectiveness and shortens the inpatient treatment time of patients.